KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Cash & Equivalents (2018 - 2025)

Castle Biosciences (CSTL) has disclosed Cash & Equivalents for 8 consecutive years, with $116.7 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents fell 2.51% to $116.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $116.7 million through Dec 2025, down 2.51% year-over-year, with the annual reading at $116.7 million for FY2025, 2.51% down from the prior year.
  • Cash & Equivalents hit $116.7 million in Q4 2025 for Castle Biosciences, up from $85.6 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $407.0 million in Q1 2021 to a low of $82.2 million in Q2 2025.
  • Historically, Cash & Equivalents has averaged $173.3 million across 5 years, with a median of $115.8 million in 2023.
  • Biggest five-year swings in Cash & Equivalents: skyrocketed 312.54% in 2021 and later plummeted 64.9% in 2023.
  • Year by year, Cash & Equivalents stood at $329.6 million in 2021, then plummeted by 62.7% to $122.9 million in 2022, then decreased by 19.61% to $98.8 million in 2023, then rose by 21.11% to $119.7 million in 2024, then decreased by 2.51% to $116.7 million in 2025.
  • Business Quant data shows Cash & Equivalents for CSTL at $116.7 million in Q4 2025, $85.6 million in Q3 2025, and $82.2 million in Q2 2025.